Ionis Pharmaceuticals Inc. (IONS)
NASDAQ:IONS
Want to see IONS full AI Analyst Report?
IONS Stock Chart & Stats
$75.71
-$0.75(-2.14%)
At close: 4:00 PM EST
$75.71
-$0.75(-2.14%)
Day’s Range― - ―
52-Week Range$33.43 - $86.74
Previous CloseN/A
Volume126.35K
Average Volume (3M)1.80M
Market Cap
$12.64B
Enterprise Value$14.51B
Total Cash (Recent Filing)$1.92B
Total Debt (Recent Filing)$2.04B
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 05, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding165,262,560
10 Day Avg. Volume1,762,917
30 Day Avg. Volume1,802,359
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)25.88
Price to Sales (P/S)13.41
P/FCF Ratio-39.55
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue13.72
Enterprise Value/Gross Profit13.95
Enterprise Value/Ebitda3.20
Forecast
1Y Price Target
$107.06Price Target Upside41.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-3.62
Revenue Forecast (FY)$890.22M
Bulls Say, Bears Say
Bulls Say
Very High Gross Margins (~98%+)Sustained gross margins near 98% reflect the ASO platform's low incremental production cost and strong product economics. High product-level margins provide durable operating leverage as commercial sales scale, improving long-term profitability potential once fixed R&D and SG&A are absorbed.
Accelerating Commercial Revenue And Raised GuidanceAn 87% YoY revenue spike and higher full-year guidance signal sustainable commercial traction and effective launch execution. Durable mix shift toward product sales reduces reliance on one-time milestones and supports repeatable revenue streams as multiple independent launches progress.
Validated Partner Pipeline With Material Milestone/royalty UpsidePositive Phase 3 partner data and tiered royalties strengthen recurring revenue optionality without full commercialization spend. Partner success de-risks parts of the pipeline, provides milestone cash inflection points, and validates Ionis' antisense platform to attract further collaborations.
Bears Say
Elevated And Worsening LeverageA materially higher debt-to-equity ratio reduces financial flexibility and increases refinancing and covenant risk if markets tighten. Persistent operating losses mean leverage remains a multi-quarter structural constraint on strategic optionality and could force dilutive financings.
Sustained Negative Free Cash FlowOngoing cash burn and negative FCF imply continued reliance on financing, milestones, or partner funds to sustain launches and R&D. This cash profile is a durable headwind to self-funded growth and elevates execution risk if access to capital or milestone timing falters.
Payer Access And Coverage Lag Risk For LaunchesDelayed payer coverage and conservative contracting timelines can materially slow adoption of newly launched specialty therapies. Structural lag in reimbursement reduces near-term revenue conversion from prescriber demand and compresses the pace at which launches translate into sustainable sales.
Ionis Pharmaceuticals News
IONS FAQ
What was Ionis Pharmaceuticals Inc.’s price range in the past 12 months?
Ionis Pharmaceuticals Inc. lowest stock price was $33.43 and its highest was $86.74 in the past 12 months.
What is Ionis Pharmaceuticals Inc.’s market cap?
Ionis Pharmaceuticals Inc.’s market cap is $12.64B.
When is Ionis Pharmaceuticals Inc.’s upcoming earnings report date?
Ionis Pharmaceuticals Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 66 days.
How were Ionis Pharmaceuticals Inc.’s earnings last quarter?
Ionis Pharmaceuticals Inc. released its earnings results on Apr 29, 2026. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.877 by $0.317.
Is Ionis Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Ionis Pharmaceuticals Inc.’s price is currently Undervalued.
Does Ionis Pharmaceuticals Inc. pay dividends?
Ionis Pharmaceuticals Inc. does not currently pay dividends.
What is Ionis Pharmaceuticals Inc.’s EPS estimate?
Ionis Pharmaceuticals Inc.’s EPS estimate is -1.06.
How many shares outstanding does Ionis Pharmaceuticals Inc. have?
Ionis Pharmaceuticals Inc. has 165,262,560 shares outstanding.
What happened to Ionis Pharmaceuticals Inc.’s price movement after its last earnings report?
Ionis Pharmaceuticals Inc. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.877. Following the earnings report the stock price went up 4.249%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in IONS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ionis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$107.06 (41.41% Upside)
$107.06 (41.41% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 344.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.8%
Last 30 Days ▲ 16.1%
Last 30 Days ▲ 16.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
128.63%
12-Months-Change
Fundamentals
Return on Equity
-58.57%
Trailing 12-Months
Asset Growth
22.65%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Company Deck
IONS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and operational momentum—substantial year-over-year revenue growth (87%), meaningful milestone receipts (~$95M), multiple regulatory milestones and expanded product launches, plus an improved full-year revenue guide and tighter operating outlook. These positives are tempered by near-term headwinds from a price reset causing expected Q2 revenue pressure, elevated operating expenses and a large (but improving) non-GAAP operating loss, potential payer access timing delays, and an observed but described-as-managed hepatic fat signal in long-term data. On balance, the company’s growth drivers, expanded launch footprint, strengthened guidance and partner-led catalysts outweigh the challenges described.View all IONS earnings summariesIONS Revenue Breakdown
60.82% R&D
39.18% Commercial
IONS Stock 12 Month Forecast
Average Price Target
$107.06
▲(41.41% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
0.74% Insiders
41.16% Mutual Funds
35.33% Other Institutional Investors
7.48% Public Companies and
Individual Investors